Table II.
Effects of BSYZ on SOD activity, and MDA and GSH content in the hippocampus of scopolamine-treated mice.
| Group | SOD (U/mg protein) | MDA (nmol/mg protein) | GSH (μg/mg protein) |
|---|---|---|---|
| Vehicle control | 45.22±1.61 | 0.25±0.11 | 5.68±1.14 |
| SCOP | 28.60±4.42a | 0.47±0.14a | 2.81±0.52a |
| SCOP + Aricept (3 mg/kg day) | 39.89±7.02b | 0.30±0.14b | 4.34±0.96b |
| SCOP + BSYZ (1.46 g/kg day) | 34.68±6.24 | 0.38±0.08 | 3.40±0.45 |
| SCOP + BSYZ (2.92 g/kg day) | 38.56±8.00b | 0.26±0.04c | 5.18±0.40c |
| SCOP + BSYZ (5.84 g/kg day) | 30.50±3.02 | 0.35±0.07 | 4.17±0.76b |
BSYZ, Bushen-Yizhi formula; SOD, superoxide dismutase; MDA, malondialdehyde; GSH, glutathione. Data are shown as the mean ± SE (n=4).
a
P<0.01 versus the vehicle control mice,
b
P<0.05 and
c
P<0.01 versus the scopolamine-treated mice.